Issue 16, 2023

New application of a periodic mesoporous nanocrystal silicon–silica composite for hyperlipidemia

Abstract

The integration of the properties of silicon nano crystallinity with silica mesoporosity provides a wealth of new opportunities for emerging biomedicine. Cholesterol (CHO) and triglyceride (TG) levels have always been a challenge for cardiologists in the treatment of patients with chronic coronary artery disease (CAD). For patients with hyperlipidemia, statins and other lipid-lowering drugs are currently recommended. It should be noted, however, that significant side effects have been reported in the treatments, including liver damage, muscle pain, etc. We here found that our previously produced periodic mesoporous nanocrystalline silicon–silica, meso-ncSi/SiO2 (PMS), a nanocomposite material, has the properties of lowering CHO and TG, and is associated with better safety and biocompatibility compared to existing lipid-lowering drugs. After being incubated with PMS for 2 hours, CHO and TG levels in blood were significantly lower than before. In addition, CHO and TG adsorbed on with PMS could also be extracted and released, contributing to the recovery and recycling of PMS.

Graphical abstract: New application of a periodic mesoporous nanocrystal silicon–silica composite for hyperlipidemia

Article information

Article type
Paper
Submitted
28 jun 2023
Accepted
08 jul 2023
First published
31 jul 2023
This article is Open Access
Creative Commons BY-NC license

Nanoscale Adv., 2023,5, 4286-4297

New application of a periodic mesoporous nanocrystal silicon–silica composite for hyperlipidemia

W. Lu, H. Jin, J. Ding, Y. Zhang and Y. Wu, Nanoscale Adv., 2023, 5, 4286 DOI: 10.1039/D3NA00467H

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements